New Systematic Review Shows Regional and Serotype Variations in Childhood Pneumococcal Immunity

A recent systematic review and meta-analysis published in npj Vaccines showed a comprehensive look at the evolving landscape of pneumococcal immunogenicity in children, offering critical insights for pharmacists managing vaccination programs. As population-level introduction of pneumococcal conjugate vaccines (PCVs) has led to an increase in invasive pneumococcal disease (IPD) caused by nonvaccine serotypes, the development of higher-valency vaccines has become a primary strategy to address these shifting threats.¹

“In this study, we conducted a systematic review and meta-analysis of post-vaccination immune responses in infants by serotype, vaccine product, dosing schedule and geographic region to define trends in CRM197-based PCV immunogenicity in children,” the study authors said.

The analysis of 250 articles involving children under the age of 2 years reveals that vaccine immunogenicity is not uniform and is significantly influenced by the specific serotype, the vaccine product, the dosing schedule, and the geographic region.

One of the most noteworthy findings for clinical practice is a general downward trend in IgG geometric mean concentrations (GMCs) as the valency of the vaccine increases. Although higher-valency vaccines such as PCV20 offer broader protection against more serotypes, the intensity of the immune response to individual serotypes often decreases compared with lower-valency options.

Specifically, serotype 3 continues to be a challenge for immunogenicity, exhibiting the lowest pooled IgG GMCs in the PCV20 childhood schedule. For pharmacists, this highlights the necessity of ensuring patients receive the full recommended series to achieve protective thresholds, as the authors note that for PCV20, IgG GMCs after only 2 primary doses remained below the 0.35 µg/mL threshold for 6 different serotypes.

The importance of the dosing regimen is underscored by the finding that IgG responses increase with the number of primary doses and are further enhanced by a booster dose, although the magnitude of this enhancement varies by serotype. This aligns with current routine recommendations from the CDC, which advise a 4-dose PCV series for all children younger than 5 years, administered at 2, 4, 6, and 12 through 15 months of age. Pharmacists can utilize tools such as the PneumoRecs VaxAdvisor app to interpret these age- and risk-based recommendations and ensure patients remain up to date.^1,2

The technological composition of these vaccines also plays a role in their effectiveness, as seen in a phase 3 trial of an experimental 13-valent vaccine that utilized both CRM197 and tetanus toxoid (TT) as carrier proteins. The trial demonstrated that the experimental vaccine was noninferior to established controls and was well-tolerated, with common adverse effects limited to mild reactions like fever or localized redness. The choice of carrier protein is significant because pre-existing immunity to the carrier, such as the tetanus toxoid, can potentially enhance the immunogenicity of the conjugated pneumococcal vaccine.³

Geographic context remains a vital consideration, as the systematic review observed regional variation in immune responses, with the highest GMCs recorded in the Western Pacific Region. These differences are often tied to the local prevalence of specific serotypes, such as 19A and 19F, which have shown varying distributions in regions like China due to factors like antibiotic pressure. For adult populations, pharmacists must also navigate a complex set of recommendations for those aged 50 years and older, where the use of PCV15, PCV20, or PCV21 is determined by the patient's prior vaccination history and specific health risks.^1-3

Ultimately, the authors suggest that even with the transition to higher-valency vaccines as a necessary response to serotype replacement, it requires a nuanced understanding of how these products perform across different populations. The robust immune responses elicited by these vaccines are essential for protecting vulnerable infants and children from severe outcomes such as pneumonia, meningitis, and bacteremia. By staying informed on the trade-offs between vaccine valency and the intensity of immune response, pharmacists can better advocate for optimized schedules that maximize both individual protection and herd immunity.^1,3

“Our systematic review provided quantitative estimates of variations in vaccine immunogenicity by serotype, vaccine type, schedule and WHO region,” the study authors concluded. “These differences should be appropriately considered when evaluating vaccine programs.”

READ MORE: Pneumococcal Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Chen X, Tavlian S, Carville KS, et al. Impact of CRM197-based conjugate vaccines, schedules, and regions on pneumococcal immunogenicity in young children: systematic review. NPJ Vaccines. Published online March 6, 2026. doi:10.1038/s41541-026-01395-y

2. CDC. Pneumococcal Vaccine Recommendations. February 25, 2026. Accessed March 25, 2026. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html

3. Xie Z, Li J, Wang X, et al. The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial. Vaccines (Basel). 2024;12(12):1417. Published 2024 Dec 16. doi:10.3390/vaccines12121417